Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes.
about
Allogeneic hematopoietic stem cell transplantation in adult acute lymphoblastic leukemia: potential benefit of medium-dose etoposide conditioningFeasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin.Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation.Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALLComparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts.Persistent complete molecular remission after nilotinib and graft-versus-leukemia effect in an acute lymphoblastic leukemia patient with cytogenetic relapse after allogeneic stem cell transplantationUKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.Immunological effects of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or philadelphia chromosome-positive acute lymphoblastic leukemiaTreatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.Clinical Trials With Mesenchymal Stem Cells: An Update.Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence.Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party oClofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results.Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation.Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia.Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT.Clinical outcome of hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL): experience from a single institution.Myeloablative unrelated cord blood transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia: comparison with other graft sources from related and unrelated donors.Pre-Transplant Consolidation is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation.Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.Pre-transplant achievement of negativity in minimal residual disease and French-American-British L1 morphology predict superior outcome after allogeneic transplant for Philadelphia chromosome positive acute lymphoblastic leukemia: an analysis of SouFrequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia.Outcome after HSCT in Philadelphia chromosome positive acute lymphoblastic leukemia in Sweden: a population-based study.
P2860
Q26795740-22633090-2810-4CD9-A8FE-58E9D56FCFA6Q33915990-06D5526B-16E9-4959-820C-067B8576C911Q34620695-88DDFB15-9DD0-4362-A0D0-7FE65E5100A6Q35057041-B23DD23C-579B-48C9-BA2D-08BE1D08029BQ35136563-B5F6F63F-A231-4FC8-8DAB-F071D2F8F161Q35243578-E2830EC8-1B70-48C9-A8DF-15B0A962EA68Q36444629-FF054C8A-BB2F-440B-A646-373A67C18677Q37564762-124C1BC3-99E8-474A-B143-DA86E5FBDF67Q37702242-9BFC81CB-ED45-411A-9793-E858D4E06CB9Q38087930-39582569-E1CD-4CA8-A99B-EC17897B658CQ38596084-E59E6930-4956-4E6E-9484-46E45213CD3AQ38698520-741BC74D-81EC-47D2-9377-64BB33F2467BQ38866851-CE5DA1E1-7C39-462A-9E2E-7D33C3722A12Q39212390-BE230C21-7B2A-4506-A4F4-A8BB36FAA8D9Q40122841-54AC873F-1D0A-4FED-8545-4F679C314382Q40365473-84775658-DBF4-4F82-8389-2D8C73CB10D4Q40519372-F67F6452-69FD-4AE2-A671-42041338C3DFQ42256587-AD62854A-DC14-482D-B180-DB52BD60B0E3Q44613089-3A44B678-1AA2-4410-853C-043771766B60Q47564576-7FFAB577-062A-4382-9C90-BE0CEA306124Q53004947-D52E03FC-E7A9-4FDB-814B-155DAB96168AQ53026373-0A2B7DBF-40F3-4C67-B912-FD41E12DE9EDQ53838406-64D27329-5533-4CD5-AEC7-A246C6C0C501Q54342246-5AF84CE0-6F73-4677-8889-AC63801DF89B
P2860
Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Long-term follow-up of allogen ...... ibitors on treatment outcomes.
@ast
Long-term follow-up of allogen ...... ibitors on treatment outcomes.
@en
type
label
Long-term follow-up of allogen ...... ibitors on treatment outcomes.
@ast
Long-term follow-up of allogen ...... ibitors on treatment outcomes.
@en
prefLabel
Long-term follow-up of allogen ...... ibitors on treatment outcomes.
@ast
Long-term follow-up of allogen ...... ibitors on treatment outcomes.
@en
P2093
P2860
P50
P1476
Long-term follow-up of allogen ...... ibitors on treatment outcomes.
@en
P2093
Alexandre Chiattone
Borje Andersson
Deborah Thomas
Elizabeth Shpall
Gabriela Rondon
Laura Worth
Marcos de Lima
Paolo Anderlini
Partow Kebriaei
Rajyalakshmi Luthra
P2860
P304
P356
10.1016/J.BBMT.2011.08.011
P577
2011-08-23T00:00:00Z